NASDAQ:BBIO

BridgeBio Pharma Competitors

$54.95
-0.80 (-1.43 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$54.23
Now: $54.95
$57.07
50-Day Range
$53.96
MA: $63.25
$71.91
52-Week Range
$25.24
Now: $54.95
$73.50
Volume558,293 shs
Average Volume1.03 million shs
Market Capitalization$8.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.82

Competitors

BridgeBio Pharma (NASDAQ:BBIO) Vs. BGNE, RPRX, GMAB, HZNP, CVAC, and CTLT

Should you be buying BBIO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to BridgeBio Pharma, including BeiGene (BGNE), Royalty Pharma (RPRX), Genmab A/S (GMAB), Horizon Therapeutics Public (HZNP), CureVac (CVAC), and Catalent (CTLT).

BeiGene (NASDAQ:BGNE) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 9.0% of BeiGene shares are held by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for BeiGene and BridgeBio Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeiGene21602.44
BridgeBio Pharma01902.90

BeiGene currently has a consensus target price of $319.3750, indicating a potential upside of 3.76%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than BeiGene.

Valuation & Earnings

This table compares BeiGene and BridgeBio Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeiGene$428.21 million65.92$-948,630,000.00($15.80)-19.48
BridgeBio Pharma$40.56 million201.80$-260,590,000.00($2.48)-22.16

BridgeBio Pharma has lower revenue, but higher earnings than BeiGene. BridgeBio Pharma is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BeiGene and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeiGene-569.22%-56.81%-39.93%
BridgeBio PharmaN/A-109.88%-48.54%

Volatility and Risk

BeiGene has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Summary

BridgeBio Pharma beats BeiGene on 9 of the 14 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and BridgeBio Pharma (NASDAQ:BBIO) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Royalty Pharma and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
BridgeBio PharmaN/A-109.88%-48.54%

Valuation & Earnings

This table compares Royalty Pharma and BridgeBio Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
BridgeBio Pharma$40.56 million201.80$-260,590,000.00($2.48)-22.16

Royalty Pharma has higher earnings, but lower revenue than BridgeBio Pharma.

Analyst Recommendations

This is a breakdown of recent recommendations for Royalty Pharma and BridgeBio Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
BridgeBio Pharma01902.90

Royalty Pharma currently has a consensus target price of $51.8750, indicating a potential upside of 24.55%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Royalty Pharma.

Summary

BridgeBio Pharma beats Royalty Pharma on 6 of the 8 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

6.2% of Genmab A/S shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 40.3% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Genmab A/S and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S50.99%34.40%30.67%
BridgeBio PharmaN/A-109.88%-48.54%

Earnings & Valuation

This table compares Genmab A/S and BridgeBio Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million28.52$324.68 million$0.5168.59
BridgeBio Pharma$40.56 million201.80$-260,590,000.00($2.48)-22.16

Genmab A/S has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Genmab A/S and BridgeBio Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S24802.43
BridgeBio Pharma01902.90

Genmab A/S presently has a consensus target price of $42.1429, indicating a potential upside of 20.48%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Genmab A/S.

Volatility & Risk

Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Summary

Genmab A/S beats BridgeBio Pharma on 8 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Horizon Therapeutics Public and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
BridgeBio PharmaN/A-109.88%-48.54%

Earnings & Valuation

This table compares Horizon Therapeutics Public and BridgeBio Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion16.12$573.02 million$1.9448.20
BridgeBio Pharma$40.56 million201.80$-260,590,000.00($2.48)-22.16

Horizon Therapeutics Public has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Horizon Therapeutics Public and BridgeBio Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public001103.00
BridgeBio Pharma01902.90

Horizon Therapeutics Public presently has a consensus target price of $111.3636, indicating a potential upside of 19.09%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Horizon Therapeutics Public.

Volatility & Risk

Horizon Therapeutics Public has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats BridgeBio Pharma on 10 of the 14 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

4.3% of CureVac shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 40.3% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares CureVac and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
BridgeBio PharmaN/A-109.88%-48.54%

Earnings & Valuation

This table compares CureVac and BridgeBio Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
BridgeBio Pharma$40.56 million201.80$-260,590,000.00($2.48)-22.16

CureVac has higher earnings, but lower revenue than BridgeBio Pharma.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for CureVac and BridgeBio Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11202.25
BridgeBio Pharma01902.90

CureVac presently has a consensus target price of $58.3333, indicating a potential downside of 43.94%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than CureVac.

Summary

BridgeBio Pharma beats CureVac on 6 of the 8 factors compared between the two stocks.

Catalent (NYSE:CTLT) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Earnings & Valuation

This table compares Catalent and BridgeBio Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion6.11$173 million$1.8859.04
BridgeBio Pharma$40.56 million201.80$-260,590,000.00($2.48)-22.16

Catalent has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Catalent and BridgeBio Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
BridgeBio Pharma01902.90

Catalent presently has a consensus target price of $125.1250, indicating a potential upside of 12.74%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Catalent.

Insider & Institutional Ownership

97.8% of Catalent shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 1.0% of Catalent shares are held by insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Catalent and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
BridgeBio PharmaN/A-109.88%-48.54%

Volatility & Risk

Catalent has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Summary

Catalent beats BridgeBio Pharma on 9 of the 14 factors compared between the two stocks.


BridgeBio Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BeiGene logo
BGNE
BeiGene
1.3$307.81-2.3%$28.23 billion$428.21 million-15.23
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.65-1.1%$25.29 billionN/A0.00Increase in Short Interest
Analyst Revision
News Coverage
Genmab A/S logo
GMAB
Genmab A/S
1.4$34.98-0.9%$22.94 billion$804.57 million27.12Decrease in Short Interest
Analyst Revision
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.51-2.2%$20.95 billion$1.30 billion25.55Insider Selling
CureVac logo
CVAC
CureVac
0.6$104.05-1.4%$19.45 billionN/A0.00Analyst Upgrade
Gap Down
Catalent logo
CTLT
Catalent
1.7$110.99-1.0%$18.89 billion$3.09 billion70.69Unusual Options Activity
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$139.02-0.5%$16.31 billion$219.75 million-17.75
Zai Lab logo
ZLAB
Zai Lab
1.4$163.60-0.8%$14.49 billion$12.98 million-53.99Analyst Report
News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$78.77-0.7%$14.32 billion$1.70 billion18.03
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$30.20-2.1%$14.28 billion$3.07 billion-52.98Analyst Report
Gap Down
Grifols logo
GRFS
Grifols
1.3$18.27-2.2%$12.56 billion$5.71 billion16.31Upcoming Earnings
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.83-0.5%$11.83 billion$16.89 billion-2.94Decrease in Short Interest
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.30-0.1%$10.78 billion$8.60 billion-5.56News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$64.13-1.6%$10.66 billion$2.32 billion53.00
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.39-1.2%$9.48 billion$2.16 billion53.12Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.63-0.9%$9.44 billionN/A0.00Increase in Short Interest
United Therapeutics logo
UTHR
United Therapeutics
1.5$201.67-0.6%$8.98 billion$1.45 billion19.08Analyst Report
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$164.05-1.6%$8.31 billion$3.34 million-21.31
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$109.58-1.5%$7.34 billion$103.71 million-24.96Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.98-1.2%$7.06 billion$87.99 million-80.93Unusual Options Activity
Gap Down
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.81-0.2%$6.86 billion$311.33 million-127.21Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$124.18-0.0%$6.67 billion$14.98 million-15.13Analyst Downgrade
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.83-2.7%$6.44 billion$150,000.00-21.62Unusual Options Activity
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.03-1.9%$5.78 billion$1.12 billion85.48
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$72.63-1.1%$5.77 billion$380.83 million-9.29
Allakos logo
ALLK
Allakos
1.7$108.14-0.5%$5.74 billionN/A-39.47Insider Selling
News Coverage
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.95-0.9%$5.56 billion$66.51 million17.70Analyst Report
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.5$41.17-1.9%$5.50 billion$4.84 billion-686.05News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$78.36-0.3%$5.49 billion$85.54 million0.00
Galapagos logo
GLPG
Galapagos
1.3$79.39-1.4%$5.20 billion$1.00 billion-12.03Analyst Report
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$75.83-1.4%$4.70 billionN/A-6.18Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.50-0.2%$4.41 billion$6.87 million-7.29Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.38-0.6%$4.28 billion$204.89 million-36.73
I-Mab logo
IMAB
I-Mab
1.2$57.14-3.6%$4.11 billion$4.31 million-1.98Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.99-0.5%$4.10 billion$806.43 million-9.63Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.47-0.0%$3.99 billion$1.11 billion23.95Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.04-3.1%$3.84 billion$117.91 million-11.16
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$46.01-18.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$77.24-1.7%$3.78 billionN/A-22.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.76-0.6%$3.60 billionN/A-6.03Analyst Revision
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.36-1.1%$3.53 billion$114.62 million-7.81Analyst Report
Insmed logo
INSM
Insmed
1.2$33.62-1.8%$3.47 billion$136.47 million-12.93
LEGN
Legend Biotech
1.2$25.80-3.7%$3.43 billion$64.39 million0.00Decrease in Short Interest
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.20-0.4%$3.39 billion$339.08 million-12.33Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.19-0.6%$3.39 billion$306.98 million-6.89News Coverage
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$92.20-2.7%$3.34 billion$26.52 million-8.12
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.15-0.4%$3.29 billion$36.13 million-70.37Unusual Options Activity
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$117.29-1.6%$3.17 billionN/A-58.35Insider Selling
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$19.77-2.7%$3.15 billion$1.17 billion-42.98
Arvinas logo
ARVN
Arvinas
1.5$63.00-0.2%$3.08 billion$42.98 million-24.61Gap Down
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.